LYZ and colorectal carcinoma: In the first experiment, we compared the therapeutic activity of L19-mIFNγ KRG, KSF-mIFNγ KRG (the KSF antibody, being specific to hen egg lysozyme, was used as a negative control of irrelevant specificity in the mouse; Supplementary Figure S12), and a commercial anti-mouse PD-1 antibody in immunocompetent Balb/c mice, bearing CT26 colorectal carcinomas (Figure 5A).